Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adverum Biotechnologies, Inc.
ADVM-043-03 was a multi-center, observational study without administration of the ADVM-043 investigational product. Subjects who participated in the ADVANCE study (ADVM-043-01; NCT02168686) were enrolled into this LTFU study for continued safety monitoring for a 2-year period.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject has A1AT deficiency and has previously received ADVM-043 gene therapy
You may not be if
The subject is unwilling or unable to participate in all required study evaluations in the long-term follow-up protocol
The subject is participating in another investigational treatment protocol
The subject is unable to understand the purpose and risks of the study or cannot provide a signed and dated informed consent form (ICF)
Clareo Health | Long-Term Follow-up Study of ADVM-043
